Functional Fluidics has partnered with Safi Biotherapeutics Inc to validate the quality and efficacy of Safi’s stem-cell-derived manufactured red blood cells (mRBCs) for sickle cell disease (SCD). This collaboration aims to support Safi’s Investigational New Drug (IND) submission, bringing their innovative transfusion therapy closer to clinical trials.

Safi’s mRBCs, which previously earned FDA Orphan Drug and Rare Pediatric Disease Designations, could address the critical shortage of matched donor blood for SCD patients. With chronic transfusions being a lifeline for many, this bioengineered solution may offer a safer, more accessible alternative.

At OxyDial, we recognize the potential of this technology to transform transfusion-dependent SCD care and commend the dedication of Functional Fluidics to support next-generation SCD therapies. If successful, manufactured RBCs could reduce alloimmunization risks and improve long-term outcomes for patients.

Read more: https://www.docwirenews.com/post/bio-company-enters-collaboration-to-support-ind-for-red-blood-cell-product-in-scd

#SickleCellDisease #SCD #Hematology #RedBloodCells #FunctionalFluidics #SafiBio #MedicalInnovation #RareDisease